In the second part of the study, A quantitative assay for JAK2V617F mutation in 136 CMPN patients by ARMS-PCR and capillary electrophoresis.
通过毛细管电泳检测患者JAK2V617F突变转录本水平，定量分析JAK2V617F突变与部分临床参数间的相关性。
In BCR-ABL fusion gene negative myeloproliferative diseases, the discovery of JAK2V617F point mutation is an important landmark.
在BCR - ABL阴性的骨髓增殖性疾病的发病机制中，JAK2V 617 F点突变的发现是一个重大的突破。
Out of other 6 IMF patients without JAK2V617F point mutation only 1 patient had thrombosis, and lower counts of platelets in perepheral blood and megakaryocytes in bone marrow.
另6例JAK2V617F点突变阴性患者仅1例有血栓史，血小板数目及骨髓巨核细胞数目相对较低。
应用推荐